Drug discovery in jeopardy

Journal of Clinical Investigation

Volumn 116, Issue 11, 2006, Pages 2837-2842

  Cuatrecasas, Pedro ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMFEBUTAMONE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPTOPRIL; CETUXIMAB; CIMETIDINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; FLUOXETINE; FOSPHENYTOIN SODIUM; GABAPENTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIGLUCERASE; LENALIDOMIDE; MEVINOLIN; PREGABALIN; PROPRANOLOL; RITUXIMAB; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; TROGLITAZONE; ZIDOVUDINE;

BREAST CANCER; COLORECTAL CANCER; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; HEAD AND NECK CANCER; HUMAN; INVESTMENT; LYMPHOMA; MULTIPLE MYELOMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW;

DRUG DESIGN; DRUG INDUSTRY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750579770     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29999     Document Type: Review

References (19)

1. Booth, B., and Zemmel, R. 2004. Prospects for productivity. Nat. Rev. Drug Discov. 3:451-456.
2. Frantz, S. 2004. FDA publishes analysis of the pipeline problem. Nat. Rev. Drug Discov. 3:279.
3. Mervis, J. 2005. Productivity counts - but the definition is key. Science. 309:726-727.
4. Wood, A.J.J. 2006. A proposal for radical changes in the drug-approval process. N. Engl. J. Med. 355:618-623.
5. Kennedy, D. 2006. FDA centennial [editorial]. Science. 312:19.
6. Miller, H.I. 2005. September 2. Improving the drug approval process [editorial]. The San Diego Union-Tribune.
7. Avorn, J. 2005. FDA standards - good enough for government work? N. Engl. J. Med. 353:969-972.
8. Okie, S. 2005. What ails the FDA? N. Engl. J. Med. 352:1063-1066.
9. Cuatrecasas, P. 1995. Corporate America: creativity held hostage. In Creative action in organizations. C.M. Ford and D.A. Gioia, editors. Sage Publications. Thousand Oaks, California, USA. 201-205.
10. Cuatrecasas, P. 1991. Devising the portfolio. In Creating the right environment for drug discovery. S.R. Walker, editor. Quay Publishing. London, United Kingdom. 51-65.
11. Graedon, J., and Graedon, T. 2005. Orphan drugs have become big business. The People's Pharmacy. http://www.peoplespharmacy.org/archives/editorial/ orphan_drugs_have_become_big_business.asp.
12. Druker, B.J. 2006. Circumventing resistance to kinase-inhibitor therapy. N. Engl. J. Med. 354:2594-2596.
13. Cuatrecasas, P. 1992. Industry-university alliances in biomedical research. J. Clin. Pharmacol. 32:100-106.
14. Duyk, G. 2003. Attrition and translation. Science. 302:603-605.
15. Kaiser, J. 2006. A cure for medicine's ailments? Science. 311:1852-1854.
16. Couzin, J. 2003. NIH dives into drug discovery. Science. 302:218-222.
17. Office of Portfolio Analysis and Strategic Initiatives. 2006. Molecular libraries and imaging: NIH Roadmap for medical research. http://nihroadmap.nih. gov/molecularlibraries/fundedresearch.asp.
18. Marks, R.M. 2006. Rescuing the NIH before it is too late [editorial]. J. Clin. Invest. 116:844. doi:10.1172/JCI28364.
19. Loscalzo, J. 2006. The NIH budget and the future of biomedical research. N. Engl. J. Med. 354:1665-1667.